Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-center trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations (NCT04886804)
1. NCT06151574. https://clinicaltrials.gov/study/NCT06151574. Accessed April 2024; 2. Wu et a. AACR 2024. Poster CT284.